🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.3871
-0.0228 (-5.56%)
At close: Nov 19, 2026, 4:00 PM EST
0.4000
+0.0129 (3.33%)
After-hours: Nov 19, 2026, 7:30 PM EST

Coherus Oncology Stock Forecast

CHRS's stock price has decreased by -68.01% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 6 analysts polled by S&P Global, Coherus Oncology stock has a consensus rating of "Buy" and an average price target of $7.25. The average 1-year stock price forecast is 1,772.90% higher than the current stock price, while the lowest is $4.00 (+933.32%) and the highest is $10 (+2,483.31%).

Price Target: $7.25 (+1,772.90%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.00$7.25$7.50$10
Change+933.32%+1772.9%+1837.5%+2483.3%

Analyst Ratings

The average analyst rating for Coherus Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Aug '26Oct '26Nov '26
Strong Buy455444
Buy111111
Hold111111
Sell000000
Strong Sell000000
Total677666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Guggenheim
Guggenheim
Buy
Maintains
$10 → $8
BuyMaintains$10 → $8+1,966.65%Nov 10, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$7
BuyMaintains$7+1,708.32%Nov 10, 2026
Maxim Group
Maxim Group
Buy
Reiterates
$4
BuyReiterates$4+933.32%Oct 30, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$10
BuyMaintains$10+2,483.31%Aug 6, 2026
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 28, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
56.71M
from 42.17M
Increased by 34.48%
Revenue Next Year
87.50M
from 56.71M
Increased by 54.28%
EPS This Year
-0.90
from -1.36
EPS Next Year
-0.62
from -0.90
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
326.55M211.04M257.24M26.39M42.17M56.71M
Revenue Growth
-31.37%-35.37%21.89%-89.74%59.81%34.48%
Gross Profit
268.96M140.96M98.25M17.66M28.36M42.54M
Gross Margin
82.36%66.79%38.19%66.93%67.24%75.00%
Operating Income
-263.86M-256.88M-193.20M-189.05M-176.43M-131.19M
Net Income
-287.10M-291.75M-237.89M28.51M168.02M-139.56M
EPS
-----1.36-0.90
Free Cash Flow
-----138.51M-84.00M
No. Analysts
-----5
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High57.0M
Avg56.7M
Low56.3M

Revenue Growth

Revenue Growth202620272028
High
35.3%
Avg
34.5%
Low
33.6%

EPS Forecast

EPS202620272028
High-0.90
Avg-0.90
Low-0.90

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-